The SEA CHANGE Study: A Self Management Intervention for Head and Neck Cancer Survivors (SEA-CHANGE)
Head and Neck Cancer
About this trial
This is an interventional supportive care trial for Head and Neck Cancer focused on measuring Head and Neck Cancer, Self-management, Intervention, Pilot Randomised Control Trial, Behavioural intervention, Quality of Life
Eligibility Criteria
Inclusion Criteria:
- had a pathologically confirmed diagnosis of an invasive primary tumour in the head and neck (oral cavity, salivary glands, nasal cavity, sinuses, middle ear, pharynx and larynx);
- have undergone and completed treatment by surgery, chemotherapy, radiotherapy or a combination thereof;
- are aged 18 or older at the time of their HNC diagnosis;
- are within 12 months of having completed their primary treatment; and
- have provided written informed, consent.
Exclusion Criteria:
- are unable to read or speak English;
- had a second invasive primary cancer other than non-melanoma skin cancer diagnosed after the HNC (as these patients are likely to be more focused on the treatment of their second cancer rather than self-management of their HNC);
- are unable to provide informed consent (e.g., if they have dementia/Alzheimer's disease); or
- have other known medical condition or other reason why they would be unable to take part.
Sites / Locations
- Royal Victoria Eye and Ear Hospital, IrelandRecruiting
- St James Hospital, IrelandRecruiting
- St Lukes Hospital, IrelandRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Usual Care arm
Intervention arm
Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.